View in EDS HTML Full Text PDF Full Text

Randomized Phase 3 Trial Evaluating the Safety, Tolerability, and Immunogenicity of V114, a 15-Valent PCV, Followed by PPSV23 6 Months Later (PNEU-DAY): Subgroup Analysis in Adults 18-49 Years of Age Enrolled at Center for Indigenous Health Sites.

Saved in:
Bibliographic Details
Title: Randomized Phase 3 Trial Evaluating the Safety, Tolerability, and Immunogenicity of V114, a 15-Valent PCV, Followed by PPSV23 6 Months Later (PNEU-DAY): Subgroup Analysis in Adults 18-49 Years of Age Enrolled at Center for Indigenous Health Sites.
Authors: Hammitt LL; Department of International Health, Center for Indigenous Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD 21205, USA., Buchwald UK; Merck & Co., Inc., Rahway, NJ 07065, USA., McCauley J; Merck & Co., Inc., Rahway, NJ 07065, USA., Shekar T; Merck & Co., Inc., Rahway, NJ 07065, USA., Fu W; Merck & Co., Inc., Rahway, NJ 07065, USA., Cheon K; Merck & Co., Inc., Rahway, NJ 07065, USA., Sterling T; Merck & Co., Inc., Rahway, NJ 07065, USA., Tamms G; Merck & Co., Inc., Rahway, NJ 07065, USA., Banniettis N; Merck & Co., Inc., Rahway, NJ 07065, USA., Musey L; Merck & Co., Inc., Rahway, NJ 07065, USA., LeBlanc JJ; Division of Microbiology, Department of Pathology and Laboratory Medicine, Nova Scotia Health, Halifax, NS B3H 1V8, Canada.; Department of Pathology, Faculty of Medicine, Dalhousie University, Halifax, NS B3K 6R8, Canada., Weatherholtz R; Department of International Health, Center for Indigenous Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD 21205, USA., Riley DP; Department of International Health, Center for Indigenous Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD 21205, USA., Denny E; Department of International Health, Center for Indigenous Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD 21205, USA., Tso C; Department of International Health, Center for Indigenous Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD 21205, USA., Roessler K; Department of International Health, Center for Indigenous Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD 21205, USA., Santosham M; Department of International Health, Center for Indigenous Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD 21205, USA.
Source: Vaccines [Vaccines (Basel)] 2025 Dec 19; Vol. 14 (1). Date of Electronic Publication: 2025 Dec 19.
Publication Type: Journal Article
Journal Info: Publisher: MDPI AG Country of Publication: Switzerland NLM ID: 101629355 Publication Model: Electronic Cited Medium: Print ISSN: 2076-393X (Print) Linking ISSN: 2076393X NLM ISO Abbreviation: Vaccines (Basel) Subsets: PubMed not MEDLINE
Database: MEDLINE Ultimate
Full text is not displayed to guests.
FullText Links:
  – Type: pdflink
Text:
  Availability: 1
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 41600920
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Randomized Phase 3 Trial Evaluating the Safety, Tolerability, and Immunogenicity of V114, a 15-Valent PCV, Followed by PPSV23 6 Months Later (PNEU-DAY): Subgroup Analysis in Adults 18-49 Years of Age Enrolled at Center for Indigenous Health Sites.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Hammitt+LL%22">Hammitt LL</searchLink>; Department of International Health, Center for Indigenous Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD 21205, USA.<br /><searchLink fieldCode="AU" term="%22Buchwald+UK%22">Buchwald UK</searchLink>; Merck & Co., Inc., Rahway, NJ 07065, USA.<br /><searchLink fieldCode="AU" term="%22McCauley+J%22">McCauley J</searchLink>; Merck & Co., Inc., Rahway, NJ 07065, USA.<br /><searchLink fieldCode="AU" term="%22Shekar+T%22">Shekar T</searchLink>; Merck & Co., Inc., Rahway, NJ 07065, USA.<br /><searchLink fieldCode="AU" term="%22Fu+W%22">Fu W</searchLink>; Merck & Co., Inc., Rahway, NJ 07065, USA.<br /><searchLink fieldCode="AU" term="%22Cheon+K%22">Cheon K</searchLink>; Merck & Co., Inc., Rahway, NJ 07065, USA.<br /><searchLink fieldCode="AU" term="%22Sterling+T%22">Sterling T</searchLink>; Merck & Co., Inc., Rahway, NJ 07065, USA.<br /><searchLink fieldCode="AU" term="%22Tamms+G%22">Tamms G</searchLink>; Merck & Co., Inc., Rahway, NJ 07065, USA.<br /><searchLink fieldCode="AU" term="%22Banniettis+N%22">Banniettis N</searchLink>; Merck & Co., Inc., Rahway, NJ 07065, USA.<br /><searchLink fieldCode="AU" term="%22Musey+L%22">Musey L</searchLink>; Merck & Co., Inc., Rahway, NJ 07065, USA.<br /><searchLink fieldCode="AU" term="%22LeBlanc+JJ%22">LeBlanc JJ</searchLink>; Division of Microbiology, Department of Pathology and Laboratory Medicine, Nova Scotia Health, Halifax, NS B3H 1V8, Canada.; Department of Pathology, Faculty of Medicine, Dalhousie University, Halifax, NS B3K 6R8, Canada.<br /><searchLink fieldCode="AU" term="%22Weatherholtz+R%22">Weatherholtz R</searchLink>; Department of International Health, Center for Indigenous Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD 21205, USA.<br /><searchLink fieldCode="AU" term="%22Riley+DP%22">Riley DP</searchLink>; Department of International Health, Center for Indigenous Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD 21205, USA.<br /><searchLink fieldCode="AU" term="%22Denny+E%22">Denny E</searchLink>; Department of International Health, Center for Indigenous Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD 21205, USA.<br /><searchLink fieldCode="AU" term="%22Tso+C%22">Tso C</searchLink>; Department of International Health, Center for Indigenous Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD 21205, USA.<br /><searchLink fieldCode="AU" term="%22Roessler+K%22">Roessler K</searchLink>; Department of International Health, Center for Indigenous Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD 21205, USA.<br /><searchLink fieldCode="AU" term="%22Santosham+M%22">Santosham M</searchLink>; Department of International Health, Center for Indigenous Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD 21205, USA.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22101629355%22">Vaccines</searchLink> [Vaccines (Basel)] 2025 Dec 19; Vol. 14 (1). <i>Date of Electronic Publication: </i>2025 Dec 19.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22MDPI+AG%22">MDPI AG </searchLink><i>Country of Publication: </i>Switzerland <i>NLM ID: </i>101629355 <i>Publication Model: </i>Electronic <i>Cited Medium: </i>Print <i>ISSN: </i>2076-393X (Print) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%222076393X%22">2076393X </searchLink><i>NLM ISO Abbreviation: </i>Vaccines (Basel) <i>Subsets: </i>PubMed not MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=41600920
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.3390/vaccines14010003
    Languages:
      – Code: eng
        Text: English
    Titles:
      – TitleFull: Randomized Phase 3 Trial Evaluating the Safety, Tolerability, and Immunogenicity of V114, a 15-Valent PCV, Followed by PPSV23 6 Months Later (PNEU-DAY): Subgroup Analysis in Adults 18-49 Years of Age Enrolled at Center for Indigenous Health Sites.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Hammitt LL
      – PersonEntity:
          Name:
            NameFull: Buchwald UK
      – PersonEntity:
          Name:
            NameFull: McCauley J
      – PersonEntity:
          Name:
            NameFull: Shekar T
      – PersonEntity:
          Name:
            NameFull: Fu W
      – PersonEntity:
          Name:
            NameFull: Cheon K
      – PersonEntity:
          Name:
            NameFull: Sterling T
      – PersonEntity:
          Name:
            NameFull: Tamms G
      – PersonEntity:
          Name:
            NameFull: Banniettis N
      – PersonEntity:
          Name:
            NameFull: Musey L
      – PersonEntity:
          Name:
            NameFull: LeBlanc JJ
      – PersonEntity:
          Name:
            NameFull: Weatherholtz R
      – PersonEntity:
          Name:
            NameFull: Riley DP
      – PersonEntity:
          Name:
            NameFull: Denny E
      – PersonEntity:
          Name:
            NameFull: Tso C
      – PersonEntity:
          Name:
            NameFull: Roessler K
      – PersonEntity:
          Name:
            NameFull: Santosham M
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 19
              M: 12
              Text: 2025 Dec 19
              Type: published
              Y: 2025
          Identifiers:
            – Type: issn-print
              Value: 2076-393X
          Numbering:
            – Type: volume
              Value: 14
            – Type: issue
              Value: 1
          Titles:
            – TitleFull: Vaccines
              Type: main
ResultId 1